Translating cancer biology into medicines

Cell cycle pioneers improving patients' healthcare
with orally available innovative medicines

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

Our Pipeline

Cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines. Cyclacel's transcriptional regulation program is evaluating CYC065, a cyclin dependent kinase (CDK) inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.

Learn more about our clinical trials:


A highly-selective, orally-available, 2nd generation inhibitor of cyclin dependent kinases (CDK) 2 and 9.

Seliciclib (CYC202)

A novel, first-in-class, orally available, cyclin dependent kinase (CDK) inhibitor.

Sapacitabine (CYC682)

An oral nucleoside analogue prodrug that acts through a novel mechanism.

Common Stock Info




Delayed at least 20 minutes.
Provided by Nasdaq.